Metformin Use and Risk of Colorectal Adenoma after Polypectomy in Patients with Type 2 Diabetes Mellitus

Amy R. Marks1, Ralph A. Pietrofesa2,3, Christopher D. Jensen1, Alexis Zebrowski2, Douglas A. Corley1, and Chyke A. Doubeni2

Abstract

Background: Existing literature suggests that metformin, the most commonly used biguanide, may lower colorectal cancer risk. Because most colorectal cancers originate in precancerous adenomas, we examined whether metformin use lowered colorectal adenoma risk after polypectomy in patients with type-2 diabetes.

Methods: Retrospective cohort study of 40- to 89-year-old Kaiser Permanente Northern California patients who had type 2 diabetes, and ≥1 adenoma detected at baseline colonoscopy during 2000 to 2009 and a repeat colonoscopy 1 to 10 years from baseline adenoma diagnosis through 2012. Cox models evaluated the association between metformin use during follow-up and subsequent adenoma diagnoses, controlling for age, race/ethnicity, sex, body mass index, and repeat examination indication.

Results: Study included 2,412 patients followed for a median of 4.5 years; cumulatively, 1,117 (46%) patients had ≥1 adenoma at repeat colonoscopy. Compared with patients not receiving diabetes medications (n = 1,578), metformin-only use (n = 457) was associated with lower adenoma recurrence risk [adjusted HR, 0.76; 95% confidence interval (CI), 0.65–0.89], and the association was stronger with increasing total metformin dose [quartile (Q) 1: HR, 0.90; 95% CI, 0.72–1.12; Q2: HR, 0.89; 95% CI, 0.70–1.12; Q3: HR, 0.80; 95% CI, 0.63–1.01; Q4: HR, 0.50; 95% CI, 0.42–0.60, P trend < 0.001]. Findings were unchanged in sensitivity analyses, including evaluating only outcomes during the 3- to 10-year period from baseline.

Conclusion: Our study suggests a potential benefit of metformin use in lowering the risk of subsequent adenomas after polypectomy in patients with type 2 diabetes.

Impact: Metformin may lower colorectal cancer risk by reducing the formation of precancerous lesions, reinforcing the potential additional benefits of its use. Cancer Epidemiol Biomarkers Prev; 24(11); 1692–8. ©2015 AACR.

Introduction

Colorectal cancer is the second leading cause of cancer-related death in the United States (1), with most originating as precancerous adenomas (2). Many patients in whom colorectal adenomas have been removed develop subsequent lesions (3–5). In the United States, based on Clinical Outcomes Research Initiative data, surveillance procedures aimed at detecting such new or recurrent lesions account for about 22% of all colonoscopies among persons 50 years and older, and is the most common reason for colonoscopy among those 75 years and older (6, 7). Thus, therapies that reduce adenoma recurrence may reduce both colorectal cancer risk and the need for surveillance colonoscopy.

Previous studies have found that commonly used medications, such as aspirin and celecoxib, may reduce adenoma and colorectal cancer risk (8–11), but there is a paucity of published studies evaluating metformin’s effect and its potential chemopreventive role. Metformin is the most commonly prescribed drug for the prevention or treatment of type 2 diabetes mellitus and associated conditions (12). Studies show that a diagnosis of diabetes is associated with an increased risk of diagnosis with colorectal adenomas and adenocarcinoma (13, 14). A number of studies have suggested that metformin may reduce colorectal cancer risk (15–18), but others have found no association (19, 20).

Materials and Methods

Study design and setting

This is a retrospective cohort study of patients receiving care in Kaiser Permanente Northern California (KPNC), an integrated healthcare delivery organization serving approximately 3.3 million people in urban, suburban, and semirural regions within a large geographic area. The integrated structure allows access to stable enrolled populations for longitudinal studies. The study...
was approved by the Institutional Review Boards of KPNC and the University of Pennsylvania.

Population
The study cohort was comprised of patients with type 2 diabetes who were 40 to 89 years old at the time they underwent a colonoscopy between January 1, 2000, and December 31, 2009, in which ≥1 histologically confirmed colorectal adenomas were found and removed. Patients were followed from the index examination date to the date of a follow-up colonoscopy on or before December 31, 2012, the last date of follow-up. We restricted the study to patients who had a repeat colonoscopy 1 to 10 years after the index examination (Fig. 1).

Patients with diabetes were identified using the Northern California Kaiser Permanente Diabetes Registry, which was started in 1993 (22). The updated criteria for inclusion in the registry are as follows: (i) one or more prescriptions within the diabetes therapeutic class, one or more inpatient diabetes diagnosis, or two or more outpatient diabetes diagnoses in a prior 5-calendar-year period; or (ii) two or more pertinent abnormal labs [serum glycosylated hemoglobin (HbA1c) ≥6.5%, fasting glucose ≥126 mg/dL, or glucose ≥200 mg/dL] in a prior two-calendar-year period. Patients with gestational diabetes, type 1 diabetes, or who were prescribed diabetes medications for indications other than type 2 diabetes, such as lipodystrophy, metabolic syndrome, prediabetes, polycystic ovaries, or amenorrhea, were excluded. Other exclusion criteria were: <2 years of health plan membership before cohort entry; history of colorectal cancer diagnosis or colectomy before or within 1 year after the index colonoscopy; and documented familial colorectal cancer syndromes such as Lynch syndrome or familial adenomatous polyposis.

To focus on new metformin users, we excluded those on diabetes medications more than 1 year before the index colonoscopy. This approach minimizes time-related biases (23) and also minimizes the potential to selectively include lesions that may have been resistant to the effect of metformin, and thus are destined to recur. This approach also minimizes the inclusion of patients who may have had diabetes for longer duration before study baseline or used metformin for indications other than type 2 diabetes. We also excluded patients who discontinued diabetes medication before the index colonoscopy; used metformin for less than 6 months; or used other diabetes medications without metformin (Fig. 1).

---

Figure 1.
Flow diagram of study participant selection. Representative flow chart of the study design and selection of patients for inclusion in the study.
Data sources
Information on clinical diagnoses was obtained from electronic databases using International Classification of Disease, Ninth Edition, Clinical Modification (ICD-9-CM) codes. Drug dispensing data were obtained from pharmacy files using National Drug Codes. Receipt of initial and follow-up colonoscopies were ascertained using Current Procedural Terminology and ICD-9-CM codes, as previously described (24). Adenoma diagnosis, location, and histology were obtained from pathology reports using Systematized Nomenclature of Medicine Clinical Terms (SNOMED) codes (24).

Outcome measurements
The primary outcome was colorectal adenoma recurrence, defined as ≥1 histologically confirmed adenoma or adenocarcinoma at the repeat colonoscopy. Person-time was computed from the index colonoscopy date. Adenoma location was classified as right colon (proximal to and including the splenic flexure, irrespective of whether adenomas were detected in the distal colon), left colon/rectum, or unspecified using SNOMED codes (24). The location was unspecified for approximately one third of baseline adenomas.

Exposure measurement
The primary exposure of interest was metformin-only use during the follow-up period based on dispensings. We also evaluated metformin used in combination with other diabetes medications, such as sulfonylureas (any-metformin). We computed the metformin total dose (with or without other diabetes medications) and adenoma recurrence risk, as either a binary variable, or according to total dispensed dose quartiles.

Results
Baseline characteristics
We identified 288,079 patients who were 40- to 89-years-old and had undergone colonoscopy during 2000 to 2009, of whom 95,927 had ≥1 histologically confirmed adenoma. Of those, 2,412 eligible patients with type 2 diabetes were included in the study (Fig. 1). The median time to repeat exam (4.5 years) did not differ significantly across exposures. On average, metformin users were on therapy for 878 days (range, 146–3,066), received 0.99 grams per day (range, 0.10–3.17), and had a total dose of 800 grams (range: 50–5,900) during the study period.

Association with adenoma recurrence risk
A total of 834 patients had used metformin, including 377 patients who received it in combination with other drugs, most commonly sulfonylurea, and 1,578 who did not receive diabetes therapy (Fig. 1). Cumulatively, 196 (42.9%) of the 457 patients on metformin-only had adenoma recurrence compared with 739 (46.8%) patients who did not receive diabetes therapy (untreated; Table 1). In Kaplan–Meier analysis, untreated patients had a higher rate of adenoma recurrence than those on metformin (Fig. 2, log-rank test P < 0.001). Cox modeling showed a 24% lower risk of adenoma recurrence (adjusted HR, 0.76; 95% CI, 0.65–0.89; Table 2) in those on metformin-only. This association was observed in analyses stratified by repeat colonoscopy indication (surveillance vs. diagnostic) on some of our analyses because of statistically significant interaction with metformin use. We also performed analyses according to baseline adenoma location (right vs. left colon) due to a priori interest and possible biologic differences in colorectal lesions according to location (31). In secondary analyses, we evaluated the association between any-metformin exposure (with or without other diabetes medications) and adenoma recurrence risk, as either a binary variable, or according to total dispensed dose quartiles.

We performed several sensitivity analyses, including limiting the cohort to new metformin initiators (n = 2,213), and to those with repeat examinations 3 to 5, or 6 to 10 years from baseline consistent with surveillance recommendations (32). Type 2 diabetes occurs insidiously and patients may remain in a prediabetic state or have undetected diabetes for many years before clinical diagnosis (33–35). We assumed this preclinical phase to be <5 years and performed analyses in which accrued person-time was computed from no further than 5 years before the diabetes diagnosis date. We also assessed the duration of therapy in our sensitivity analyses (Supplementary Table S1). Because of reports of potential gender differences in the association between having diabetes and colorectal neoplasia risk, we performed further analysis stratified on gender (36), although there was no statistically significant gender–metformin interaction observed. We examined and did not find a statistically significant association with level of glycemic control based on an HbA1C of ≤7% versus higher. All analyses were performed using SAS 9.3 software (SAS Institute).

Statistical analyses
We first used the Kaplan–Meier product limit estimator to evaluate the association between metformin use and adenoma recurrence risk. Multilevel Cox proportional hazard models with clustering on the performing provider were used to estimate HRs and 95% confidence intervals (CI) for the association between exposure to metformin in the 1- to 10-year period after the index colonoscopy and risk of adenoma recurrence. The reference group in all analyses was patients who did not receive any diabetes medications during the study period. Multivariable models were adjusted for the covariates noted above, except HbA1c, which was not statistically significantly associated with adenoma recurrence risk (P > 0.05), and did not influence the main effects. We stratified on repeat colonoscopy indication (surveillance vs. diagnostic) on some of our analyses because of statistically significant interaction with metformin use. We also performed analyses according to baseline adenoma location (right vs. left colon) due to a priori interest and possible biologic differences in colorectal lesions according to location (31).
However, the association was not statistically significant for left colon lesions or surveillance examinations. In secondary analyses, any-metformin use (alone and in combination with other diabetes medications) was similarly associated with a lower adenoma recurrence risk (adjusted HR, 0.74; CI 0.66–0.84; Table 2). The risk of adenoma recurrence was monotonically lower with increasing total dose. Compared with no therapy, and with increasing quartiles denoting increasing dose, the adjusted HR was 0.90 (95% CI, 0.72–1.12) for Q1, 0.89 (95% CI, 0.70–1.12) for Q2, 0.80 (95% CI, 0.63–1.01) for Q3, and 0.75 (95% CI, 0.56–1.00) for Q4.

Figure 2.
Kaplan–Meier curves of relationship of metformin use and adenoma recurrence. The curves are stratified by indication for the repeat examination. The log-rank test P values were as follows (compared to no diabetes medications): for surveillance, 0.051 for metformin-only and 0.002 for metformin plus other; for diagnostic, <0.001 for both metformin-only and metformin plus other.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No diabetes medication (n = 1,578)</th>
<th>Metformin-only (n = 457)</th>
<th>Metformin plus other (n = 377)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at baseline, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40–49</td>
<td>54 (3.4)</td>
<td>27 (5.9)</td>
<td>33 (8.8)</td>
</tr>
<tr>
<td>50–54</td>
<td>164 (10.4)</td>
<td>71 (15.5)</td>
<td>79 (21.0)</td>
</tr>
<tr>
<td>55–59</td>
<td>199 (12.6)</td>
<td>83 (18.2)</td>
<td>80 (21.2)</td>
</tr>
<tr>
<td>60–64</td>
<td>289 (18.5)</td>
<td>94 (20.6)</td>
<td>72 (19.3)</td>
</tr>
<tr>
<td>65–69</td>
<td>322 (20.4)</td>
<td>74 (16.2)</td>
<td>64 (17.0)</td>
</tr>
<tr>
<td>70–74</td>
<td>318 (20.2)</td>
<td>75 (16.0)</td>
<td>32 (8.5)</td>
</tr>
<tr>
<td>75+</td>
<td>232 (14.7)</td>
<td>35 (7.7)</td>
<td>17 (4.5)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>575 (36.4)</td>
<td>178 (38.9)</td>
<td>149 (39.5)</td>
</tr>
<tr>
<td>Male</td>
<td>1,003 (63.6)</td>
<td>279 (61.1)</td>
<td>228 (60.5)</td>
</tr>
<tr>
<td>Race/ethnicity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic white</td>
<td>943 (59.8)</td>
<td>253 (55.4)</td>
<td>222 (58.9)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>199 (12.6)</td>
<td>64 (14.0)</td>
<td>57 (15.1)</td>
</tr>
<tr>
<td>Black</td>
<td>112 (7.1)</td>
<td>33 (7.2)</td>
<td>16 (4.2)</td>
</tr>
<tr>
<td>Asian/Pacific Islander</td>
<td>216 (13.7)</td>
<td>76 (16.6)</td>
<td>48 (12.7)</td>
</tr>
<tr>
<td>Other*</td>
<td>108 (6.8)</td>
<td>31 (6.8)</td>
<td>34 (9.0)</td>
</tr>
<tr>
<td>BMI closest to baseline exam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;25.0</td>
<td>208 (13.2)</td>
<td>42 (9.2)</td>
<td>30 (8.0)</td>
</tr>
<tr>
<td>25.0–29.9</td>
<td>484 (30.7)</td>
<td>109 (23.9)</td>
<td>76 (20.2)</td>
</tr>
<tr>
<td>30+</td>
<td>801 (50.8)</td>
<td>279 (61.1)</td>
<td>252 (66.8)</td>
</tr>
<tr>
<td>Unknown</td>
<td>85 (5.4)</td>
<td>27 (5.9)</td>
<td>19 (5.0)</td>
</tr>
<tr>
<td>Indication for repeat exam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveillance</td>
<td>844 (53.5)</td>
<td>279 (61.1)</td>
<td>206 (54.6)</td>
</tr>
<tr>
<td>Diagnostic</td>
<td>734 (46.5)</td>
<td>178 (38.9)</td>
<td>171 (45.4)</td>
</tr>
<tr>
<td>Recurrent adenoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>839 (53.2)</td>
<td>261 (57.1)</td>
<td>195 (51.7)</td>
</tr>
<tr>
<td>Any</td>
<td>739 (46.8)</td>
<td>196 (42.9)</td>
<td>182 (48.3)</td>
</tr>
<tr>
<td>Mean HbA1c, mean (SD; n = 2,293)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6.18 (0.59)</td>
<td>6.73 (0.72)</td>
<td>7.35 (0.88)</td>
<td></td>
</tr>
<tr>
<td>Time to repeat exam, median (IQR)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.1 (2.4)</td>
<td>4.9 (2.5)</td>
<td>5.2 (2.6)</td>
<td></td>
</tr>
</tbody>
</table>

*Other race/ethnicity includes Native American, multiracial/other, and unknown.
Table 2. Associations between metformin use and risk of colorectal adenoma recurrence in patients with type 2 diabetes

<table>
<thead>
<tr>
<th>Exposure categories</th>
<th>Total dose, quartiles</th>
<th>Quartile 1</th>
<th>Quartile 2</th>
<th>Quartile 3</th>
<th>Quartile 4</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(adjusted OR, 95% CI)</td>
<td>(0.00–0.33)</td>
<td>(0.34–0.66)</td>
<td>(0.67–0.97)</td>
<td>(0.98–1.37)</td>
</tr>
<tr>
<td>No diabetes medication (reference)</td>
<td>1.00 (0.99–1.01)</td>
<td>1.00 (0.98–1.02)</td>
<td>1.00 (0.97–1.02)</td>
<td>1.00 (0.96–1.04)</td>
<td></td>
</tr>
<tr>
<td>Any metformin</td>
<td>0.86 (0.76–0.98)</td>
<td>0.85 (0.76–1.02)</td>
<td>0.85 (0.71–1.00)</td>
<td>0.85 (0.74–0.96)</td>
<td></td>
</tr>
<tr>
<td>Total dose, quartiles</td>
<td>0.86 (0.76–0.98)</td>
<td>0.85 (0.76–1.02)</td>
<td>0.85 (0.71–1.00)</td>
<td>0.85 (0.74–0.96)</td>
<td></td>
</tr>
<tr>
<td>Quartile 2</td>
<td>0.80 (0.63–0.97)</td>
<td>0.70 (0.59–0.84)</td>
<td>0.69 (0.57–0.84)</td>
<td>0.65 (0.52–0.81)</td>
<td></td>
</tr>
<tr>
<td>Quartile 3</td>
<td>0.50 (0.42–0.60)</td>
<td>0.40 (0.30–0.52)</td>
<td>0.38 (0.28–0.52)</td>
<td>0.35 (0.24–0.51)</td>
<td></td>
</tr>
<tr>
<td>Quartile 4</td>
<td>0.27 (0.20–0.37)</td>
<td>0.20 (0.14–0.28)</td>
<td>0.18 (0.13–0.25)</td>
<td>0.16 (0.11–0.25)</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: Models were run separately for each set of exposure categories. All models are adjusted for age category, sex, race/ethnicity, BMI, and indication for repeat examination, as appropriate.

Published OnlineFirst September 16, 2015; DOI: 10.1158/1055-9965.EPI-15-0559

Discussion

We found that, in patients with type 2 diabetes, metformin use was associated with a lower risk of colorectal adenoma recurrence when compared with no diabetes therapy. The observed risk was inversely related to metformin total dose and was stable in various sensitivity analyses, excluding models that were restricted to new therapy initiators. These findings suggest that, in addition to its established role in treating diabetes and related conditions, metformin use may also confer additional benefits in lowering the risk of adenoma.

The association of metformin with colorectal cancer or adenoma risk is controversial. Our findings are consistent with, and support previous reports that metformin use was associated with colorectal cancer risk. Our findings were stable in various secondary and sensitivity analyses. This study’s findings may also suggest a potential explanation for how metformin may lower colorectal cancer risk through the adenoma–cancer sequence. Metformin’s effect on adenoma risk could be mediated through several posited biologic mechanisms such as mechanistic target of rapamycin (mTOR) pathway inhibition and insulin-like growth factor signaling suppression (37).

There are no previous studies to directly compare with ours, but Lee and colleagues (38) reported that, in patients with type 2 diabetes who had undergone colorectal cancer resection, metformin use was associated with lower odds (OR, 0.27; 95% CI, 0.10–0.76) of recurrent adenoma. Kanadiya and colleagues (21) also reported that metformin use was associated with lower odds (OR, 0.55; 95% CI, 0.34–0.87) of adenoma in a study of 405 patients with type 2 diabetes undergoing screening colonoscopy (n = 148). In contrast, our study examined adenoma risk during the surveillance phase of the cancer care continuum on a large cohort of 2,412 patients, with 834 exposed to metformin. Our design addressed several potential time-related biases of observational studies (23).

Our study has some potential limitations. First, we restricted the follow-up time to the first repeat colonoscopy, which limited the time interval for detecting recurrent lesions as well as our ability for direct causal inference. However, there was no substantive difference in the follow-up time according to exposure group. Also, we could not account for exposure to other potential adenoma chemopreventive strategies, such as COX-2 inhibitors, aspirin and other non-steroidal anti-inflammatory drugs, statins, lifestyle factors, smoking history, and dietary factors such as folic acid and calcium (9–11, 39–41).

In conclusion, we found an inverse association between metformin use and risk of adenoma recurrence in patients with type 2 diabetes that was independent of other factors assessed. These findings suggest a possible role for metformin in the secondary chemoprevention of adenomas.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: R.A. Pietrofesa, A. Zebrowski, D.A. Corley, C.A. Doubeni
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A.R. Marks, D.A. Corley, C.A. Doubeni
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A.R. Marks, R.A. Pietrofesa, C.D. Jensen, D.A. Corley, C.A. Doubeni
Writing, editing, and/or revision of the manuscript: A.R. Marks, R.A. Pietrofesa, C.D. Jensen, A. Zebrowski, D.A. Corley, C.A. Doubeni
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.R. Marks, R.A. Pietrofesa, C.A. Doubeni
Study supervision: D.A. Corley, C.A. Doubeni

References
30. Yang YX, Habel LA, Capra AM, Achacoso NS, Quesenberry CP Jr, Ferrara A, et al. Serial glycosylated hemoglobin levels and risk of colorectal neoplasia...
Metformin Use and Risk of Colorectal Adenoma after Polypectomy in Patients with Type 2 Diabetes Mellitus

Amy R. Marks, Ralph A. Pietrofesa, Christopher D. Jensen, et al.

Cancer Epidemiol Biomarkers Prev 2015;24:1692-1698. Published OnlineFirst September 16, 2015.

Access the most recent version of this article at: doi:10.1158/1055-9965.EPI-15-0559

Access the most recent supplemental material at: http://cebp.aacrjournals.org/content/suppl/2015/09/16/1055-9965.EPI-15-0559.DC1

This article cites 41 articles, 10 of which you can access for free at: http://cebp.aacrjournals.org/content/24/11/1692.full#ref-list-1

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.